Particularly, somatic mutations in ANKRD1, FASN, and TP53 were identified in both PGCA and adenocarcinoma components, with these alterations demonstrating significant associations with adverse prognosis in PCa (Figure 3A). The gene discussed is FASN; the disease is adenocarcinoma.